Biodesix (BDSX) Research & Development (2019 - 2026)

Biodesix (BDSX) has reported Research & Development for 8 consecutive years, with $3.3 million the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $3.3 million, up 14.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 19.51% YoY), and the FY2025 annual result was $12.0 million, up 25.55% from the prior year.
• Research & Development was $3.3 million for Q1 2026 at Biodesix, up from $2.9 million in the prior quarter.
• Over five years, Research & Development peaked at $3.6 million in Q4 2022 and troughed at $1.9 million in Q4 2023.
• Average Research & Development over 5 years is $2.8 million, with a median of $2.9 million recorded in 2023.
• Year-over-year, Research & Development slumped 47.01% in 2023 and soared 40.69% in 2025.
• Over 5 years, Research & Development stood at $3.6 million in 2022, then slumped by 47.01% to $1.9 million in 2023, then rose by 27.79% to $2.4 million in 2024, then grew by 18.89% to $2.9 million in 2025, then rose by 14.46% to $3.3 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $3.3 million in Q1 2026, $2.9 million in Q4 2025, and $3.0 million in Q3 2025.